CD8A and inflammatory bowel disease: It is largely accepted that CXCL10 promotes the activity of effector CD4+ and CD8+ T cells, and also their recruitment at inflammatory sites (also tumor site) and thus its targeted neutralization could be beneficial in treating various T cell mediated autoimmune diseases among them: psoriasis, rheumatoid arthritis (RA) (27, 28), Inflammatory Bowel Disease [IBD) (29), and type I diabetes (T1DM) (30, 31) (for a recent review also see (32)] (Figure 1B).